At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.
In Brief
A Phase 2 clinical trial evaluating Pazopanib for Macular Degeneration. Completed, enrolled 70 participants across 27 sites in 4 countries.
Detailed Summary
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesAustralia, Belgium, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMar 2008
Primary CompletionJan 2009
Study CompletionJun 2009
TodayJul 2026
First PostedFeb 11, 2008
Enrollment StartMar 5, 2008
Primary CompletionJan 1, 2009
Study CompletionJun 17, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.4 years ago
Interventions
Pazopanibdrug
Pazopanib eye drops formulation